EP0721328A4 - Camptothecin formulations - Google Patents

Camptothecin formulations

Info

Publication number: EP0721328A4
Authority: EP; European Patent Office
Prior art keywords: camptothecin formulations; camptothecin; formulations
Prior art date: 1993-09-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP94929892A

Other languages

German (de)

French (fr)

Other versions

EP0721328A1 (en

Inventor

Panayiotis Peri Constantinides

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

SmithKline Beecham Corp

Original Assignee

SmithKline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-09-27

Filing date

1994-09-27

Publication date

1997-09-17

1994-09-27 Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp

1996-07-17 Publication of EP0721328A1 publication Critical patent/EP0721328A1/en

1997-09-17 Publication of EP0721328A4 publication Critical patent/EP0721328A4/en

Status Withdrawn legal-status Critical Current

Links

KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 title 1
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 title 1
229940127093 camptothecin Drugs 0.000 title 1
VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 title 1
238000009472 formulation Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Dispersion Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP94929892A 1993-09-27 1994-09-27 Camptothecin formulations Withdrawn EP0721328A4 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US12720893A	1993-09-27	1993-09-27
PCT/US1994/010898 WO1995008986A1 (en)	1993-09-27	1994-09-27	Camptothecin formulations
US127208		1998-07-31

Publications (2)

Publication Number	Publication Date
EP0721328A1 EP0721328A1 (en)	1996-07-17
EP0721328A4 true EP0721328A4 (en)	1997-09-17

Family

ID=22428860

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP94929892A Withdrawn EP0721328A4 (en)	1993-09-27	1994-09-27	Camptothecin formulations

Country Status (3)

Country	Link
EP (1)	EP0721328A4 (en)
JP (1)	JPH09504517A (en)
WO (1)	WO1995008986A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL115099A (en) *	1994-10-14	1999-04-11	Upjohn Co	Lyophilizate of phospholipid complex of water insoluble camptothecins
US5827533A (en) *	1997-02-06	1998-10-27	Duke University	Liposomes containing active agents aggregated with lipid surfactants
WO1999013816A2 (en) *	1997-09-16	1999-03-25	Nexstar Pharmaceuticals, Inc.	Liposomal camptothecin formulations
US6726925B1 (en)	1998-06-18	2004-04-27	Duke University	Temperature-sensitive liposomal formulation
US6200598B1 (en)	1998-06-18	2001-03-13	Duke University	Temperature-sensitive liposomal formulation
BR9914601A (en) *	1998-09-16	2001-10-23	Alza Corp	Liposome-captured topoisomerase inhibitor
ATE286741T1 (en) *	1999-01-27	2005-01-15	Telik Inc	THERAPEUTIC COMPOSITIONS CONTAINING GLUTATHIONE ANALOGUES
US7311924B2 (en)	1999-04-01	2007-12-25	Hana Biosciences, Inc.	Compositions and methods for treating cancer
US7244448B2 (en) *	2000-06-30	2007-07-17	Tekmira Pharmaceuticals Corporation	Liposomal antineoplastic drugs and uses thereof
US7452550B2 (en)	2000-06-30	2008-11-18	Hana Biosciences, Inc.	Liposomal antineoplastic drugs and uses thereof
US6828306B2 (en) *	2000-07-31	2004-12-07	Ottawa Heart Institute Research Corporation	Charged lipid compositions and methods for their use
SK7092003A3 (en) *	2000-11-09	2004-06-08	Neopharm Inc	SN-38 lipid complexes and methods of use
US7691872B2 (en) *	2001-03-20	2010-04-06	University Of Kentucky Research Foundation	Methods and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds
DE10157994A1 (en) *	2001-05-25	2003-01-02	G O T Therapeutics Gmbh	Liposomally encapsulated hydrophobic active ingredients with a high active ingredient content> 50% and methods for producing pharmaceutical preparations which comprise liposomally encapsulated hydrophobic active ingredients
WO2003030864A1 (en)	2001-05-29	2003-04-17	Neopharm, Inc.	Liposomal formulation of irinotecan
GB0207653D0 (en) *	2002-04-03	2002-05-15	Lamellar Therapeutics Ltd	Methods of using lamellar bodies for therapeutic purposes
WO2004002455A1 (en) *	2002-06-26	2004-01-08	Medigene Oncology Gmbh	Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system
EP1393719A1 (en) *	2002-08-23	2004-03-03	Munich Biotech AG	Camptothecin-carboxylate formulations
JP2006526412A (en)	2003-05-30	2006-11-24	ユニバーシティオブシカゴ	Methods and compositions for estimating irinotecan toxicity
EP1643972A4 (en) *	2003-06-27	2010-01-20	Smithkline Beecham Corp	Stabilized topotecan liposomal composition and methods
GB0322448D0 (en)	2003-09-25	2003-10-29	Lamellar Therapeutics Ltd	Using lamellar bodies to modify linear biological macro molecules
US7811602B2 (en)	2004-05-17	2010-10-12	Tekmira Pharmaceuticals Corporation	Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
CN100356919C (en) *	2004-05-31	2007-12-26	上海医药工业研究院	Hydroxycamptothecin liposome and its preparation
JP4885715B2 (en)	2004-06-01	2012-02-29	テルモ株式会社	Irinotecan formulation
AU2005253852B2 (en) *	2004-06-18	2008-05-29	Kabushiki Kaisha Yakult Honsha	Liposome preparation containing slightly water-soluble camptothecin
US20090285878A1 (en) *	2004-11-05	2009-11-19	Tekmira Pharmaceuticals Corporation	Compositions and methods for stabilizing liposomal drug formulations
EP1676568A1 (en) *	2004-12-30	2006-07-05	Merckle Gmbh	Particles comprising phospholipids, process of preparation and use as medicament
US8206750B2 (en)	2005-03-24	2012-06-26	Cerenis Therapeutics Holding S.A.	Charged lipoprotein complexes and their uses
WO2011076807A2 (en)	2009-12-23	2011-06-30	Novartis Ag	Lipids, lipid compositions, and methods of using them
CN102516258B (en) *	2011-11-11	2014-06-25	正大天晴药业集团股份有限公司	Fat-soluble anticancer drug compound and preparation modified by water-soluble vitamin E derivative, preparation method and application of the compound
WO2014015027A1 (en) *	2012-07-18	2014-01-23	Onyx Therapeutics, Inc.	Liposomal compositions of epoxyketone-based proteasome inhibitors
US9801874B2 (en)	2012-11-20	2017-10-31	Spectrum Pharmaceuticals	Method for the preparation of liposome encapsulated vincristine for therapeutic use
EP3608308B1 (en)	2013-03-08	2021-07-21	Novartis AG	Lipids and lipid compositions for the delivery of active agents
EP4019506A1 (en)	2013-12-19	2022-06-29	Novartis AG	Lipids and lipid compositions for the delivery of active agents
ES2895651T3 (en)	2013-12-19	2022-02-22	Novartis Ag	Lipids and lipid compositions for the administration of active agents
EP3169309B1 (en)	2014-07-16	2023-05-10	Novartis AG	Method of encapsulating a nucleic acid in a lipid nanoparticle host
US10125092B2 (en)	2014-09-05	2018-11-13	Novartis Ag	Lipids and lipid compositions for the delivery of active agents
TWI678213B (en)	2015-07-22	2019-12-01	美商史倍壯製藥公司	A ready-to-use formulation for vincristine sulfate liposome injection
JP2023546175A (en)	2020-10-14	2023-11-01	ジョージ・メイソン・リサーチ・ファウンデーション・インコーポレイテッド	Method for producing lipid nanoparticles and compositions derived therefrom
PL439632A1 (en) *	2021-11-23	2023-05-29	Uniwersytet Warszawski	Lipid drug carrier, a pharmaceutical formulation, uses thereof and method for producing a lipid drug carrier, a carrier prepared by such method and its applications

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994026253A1 (en) *	1993-05-19	1994-11-24	The Liposome Company, Inc.	Liposome having a multicomponent bilayer which contains a bioactive agent as an integral component of the bilayer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4721612A (en) *	1984-04-12	1988-01-26	The Liposome Company, Inc.	Steroidal liposomes

1994
- 1994-09-27 JP JP7510405A patent/JPH09504517A/en active Pending
- 1994-09-27 WO PCT/US1994/010898 patent/WO1995008986A1/en not_active Ceased
- 1994-09-27 EP EP94929892A patent/EP0721328A4/en not_active Withdrawn

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994026253A1 (en) *	1993-05-19	1994-11-24	The Liposome Company, Inc.	Liposome having a multicomponent bilayer which contains a bioactive agent as an integral component of the bilayer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9508986A1 *

Also Published As

Publication number	Publication date
JPH09504517A (en)	1997-05-06
WO1995008986A1 (en)	1995-04-06
EP0721328A1 (en)	1996-07-17

Legal Events

Date	Code	Title	Description
1996-05-31	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
1996-07-17	17P	Request for examination filed	Effective date: 19960402
1996-07-17	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): BE CH DE FR GB IT LI NL
1997-09-17	A4	Supplementary search report drawn up and despatched	Effective date: 19970731
1997-09-17	AK	Designated contracting states	Kind code of ref document: A4 Designated state(s): BE CH DE FR GB IT LI NL
2000-09-29	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2000-11-15	18D	Application deemed to be withdrawn	Effective date: 20000401

Publication	Publication Date	Title
EP0721328A4 (en)	1997-09-17	Camptothecin formulations
IL111004A0 (en)	1994-11-28	Oral rapamycin formulations
GB9207832D0 (en)	1992-05-27	Formulations
ZA945653B (en)	1995-03-15	Therapeutic compositions
GB9325644D0 (en)	1994-02-16	Novel formulation
ZA946195B (en)	1995-05-22	Anthelmintic formulations
GB9410252D0 (en)	1994-07-13	Galenic formulations
GB9214390D0 (en)	1992-08-19	Formulations
GB9311030D0 (en)	1993-07-14	Pharmaceutical formulations
GB9323399D0 (en)	1994-01-05	Pharmaceutical formulations
GB9308622D0 (en)	1993-06-09	Formulations
GB9306144D0 (en)	1993-05-19	Formulations
GB9213271D0 (en)	1992-08-05	Formulations
GB9224539D0 (en)	1993-01-13	Formulations
GB9202474D0 (en)	1992-03-18	Formulations
GB9205738D0 (en)	1992-04-29	Formulations
GB9205739D0 (en)	1992-04-29	Formulations
GB9321676D0 (en)	1993-12-08	Pharmaceutical formulations
GB9314443D0 (en)	1993-08-25	Pharmaceutical formulations
GB9302908D0 (en)	1993-03-31	Pharmaceutical formulations
GB9304800D0 (en)	1993-04-28	Pharmaceutical formulations
GB9301250D0 (en)	1993-03-17	Pharmaceutical formulations
GB9315119D0 (en)	1993-09-01	Pharmaceutical formulations
GB9304799D0 (en)	1993-04-28	Pharmaceutical formulations
GB9304797D0 (en)	1993-04-28	Pharmaceutical formulations